healthcare.digital July 13, 2024
Exec Summary
Danuglipron is an experimental weight loss medication being developed by Pfizer. It’s important to remember that it is not currently approved for use by any health authority. Here’s a breakdown of what we know so far:
Type of Drug: Danuglipron belongs to a class of drugs called GLP-1 receptor agonists. These medications work by mimicking a natural hormone that helps regulate blood sugar and appetite.
Promising Results: Early trials showed promising weight loss results, with participants losing an average of 5-13% of their body weight after taking Danuglipron for several months.
Challenges: Unfortunately, the trials also reported high rates of side effects, primarily nausea, vomiting, and diarrhea. These...
Today's Sponsors
Today's Sponsor